Recent advances in radiosensitivity determinants in melanoma.
Authors : Krayem M, Ghanem GE, Van Gestel D
Year : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 131-138
Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.
Authors : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE
Year : 2022
Journal : Cells
Volume : 11
The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease.
Authors : AlGhamdi H, Dhont J, Krayem M, De Bruyn P, Engels B, Van Gestel D, Van den Begin R
Year : 2022
Journal : Cancers (Basel)
Volume : 14
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.
Authors : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A
Year : 2022
Journal : Cells
Volume : 11
Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].
Authors : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Year : 2022
Journal : Eur J Cancer
Volume : 175
Pages : 336-338
The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells.
Authors : Ajouaou Y, Azouz A, Taquin A, Denanglaire S, Hussein H, Krayem M, Andris F, Moser M, Goriely S, Leo O
Year : 2022
Journal : Elife
Volume : 11
Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.
Authors : Najem A, Wouters J, Krayem M, Rambow F, Sabbah M, Sales F, Awada A, Aerts S, Journe F, Marine JC, Ghanem GE
Year : 2021
Journal : Front Oncol
Volume : 11
Pages : 780654
Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.
Authors : Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M
Year : 2021
Journal : Front Oncol
Volume : 11
Pages : 784947
Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments.
Authors : de Bakker T, Journe F, Descamps G, Saussez S, Dragan T, Ghanem G, Krayem M, Van Gestel D
Year : 2021
Journal : Front Oncol
Volume : 11
Pages : 799993
New horizons in early drugs development in solid cancers.
Authors : Kotecki N, Kindt N, Krayem M, Awada A
Year : 2021
Journal : Curr Opin Oncol
Volume : 33
Pages : 513-519
Downregulation of the FTO m<sup>6</sup>A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.
Authors : Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, Wimana Z, Calonne E, Hassabi B, Morandini R, Deplus R, Putmans P, Dube G, Singh NK, Koch A, Shostak K, Rizzotto L, Ross RL, Desmedt C, Bareche Y, Rothé F, Lehmann-Che J, Duterque-Coquillaud M, Leroy X, Menschaert G, Teixeira L, Guo M, Limbach PA, Close P, Chariot A, Leucci E, Ghanem G, Yuan BF, Willard-Gallo K, Sotiriou C, Marine JC, Fuks F
Year : 2021
Journal : Nat Cancer
Volume : 2
Pages : 611-628
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Authors : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Year : 2021
Journal : Mol Cancer Res
Volume : 19
Pages : 1221-1233
RTK Inhibitors in Melanoma: From Bench to Bedside.
Authors : Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem G
Year : 2021
Journal : Cancers (Basel)
Volume : 13
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis.
Authors : Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem G, Saussez S, Colet JM, Journe F
Year : 2020
Journal : Cancers (Basel)
Volume : 12
Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms.
Authors : Soumoy L, Wells M, Najem A, Krayem M, Ghanem G, Hambye S, Saussez S, Blankert B, Journe F
Year : 2020
Journal : Biology (Basel)
Volume : 9
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.
Authors : Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Year : 2020
Journal : Cancers (Basel)
Volume : 12
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>
Authors : Krayem M, Aftimos P, Najem A, Hooven TVD, Berg AVD, Hovestad-Bijl L, Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Year : 2020
Journal : Cancers (Basel)
Volume : 12
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.
Authors : Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem G, Van Gestel D
Year : 2019
Journal : Cancers (Basel)
Volume : 11
Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.
Authors : Chi VLD, Garaud S, De Silva P, Thibaud V, Stamatopoulos B, Berehad M, Gu-Trantien C, Krayem M, Duvillier H, Lodewyckx JN, Willard-Gallo K, Sibille C, Bron D
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 81
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
Authors : Krayem M, Najem A, Journe F, Morandini R, Sales F, Awada A, Ghanem G
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 31888-31903